Lung Cancer

The FDA approved entrectinib for pediatric and adult patients with certain subtypes of solid tumors, including non-small cell lung cancer.

While the treatment landscape for lung cancer continues to grow, nurses must stay up-to-date on the most recent advances and approvals across each subgroup of patients.

From long-term data to additional clinical trials, more is needed to better understand immunotherapy in lung cancer.

One expert discusses the arrival of immunotherapy, as well as other exciting advances, for the treatment of patients with small cell lung cancer.

Optimizing the methods for preclinical research with an emphasis on patient-derived models, may help speed up the translation of new treatment advances from the laboratory to the clinic, according to a presentation by Charles M. Rudin, MD, PhD, at the 2019 International Lung Cancer Congress.

Nurse coordinators and other healthcare professionals must work together to provide comprehensive lung cancer screening programs.

Immunotherapy has drastically changed the treatment landscape for non-small cell lung cancer, but how can practitioners decide who should get frontline chemotherapy, too?

Selective inhibitors for patients with non–small cell lung cancer with rare oncogenic drivers are showing high response rates in clinical trials, explained one expert.

When it comes to molecular testing to advance the field of lung cancer, coordinated efforts between providers—and institutions nationwide—are key.

The Food and Drug Administration approved bevacizumab-bvzr (Zirabev) – a biosimilar for bevacizumab (Avastin) for the treatment of metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.

Personalized treatments are drastically improving the outcomes of patients with non-small cell lung cancer, but there is still work to be done when it comes to understanding drug resistance.

Oncology nurses shouldn’t be concerned if patients with non-small cell lung cancer experience skin toxic effects after immunotherapy.

Patients with higher tumor mutational burdens tended to be more likely to be depressed, according to recent research.

The FDA approved pembrolizumab (Keytruda) for patients with advanced small cell lung cancer (SCLC) who experienced disease progression after 2 or more prior lines of therapy.

Patients with lung cancer often report feelings of stigma, and different approaches to care than in other cancer settings.

Broader clinical trial criteria could nearly double the number of patients with advanced non-small cell lung cancer who are eligible to participate.

Healthcare providers should not base cancer care with immune checkpoint inhibitors on gender, according to recent study findings.

In non–small cell lung cancer (NSCLC), KRAS G12 mutations have been historically difficult to target, and research efforts dedicated to the development of effective targeted therapies for NRG1 fusions have not been successful. However, several biopharmaceutical companies are in the early stages of addressing that challenge, explained Sai-Hong I. Ou, MD, PhD.

The FDA has approved the NovoTTF-100L System in combination with pemetrexed and platinum-based chemotherapy for the frontline treatment of patients with unresectable, locally advanced or metastatic malignant pleural mesothelioma (MPM), marking the first treatment for this patient population in more than 15 years.

Liquid biopsies are becoming essential in the lung cancer arena.

There are certain indicators for patients with lung cancer who may progress on osimertinib.

The FDA has expanded the approval for pembrolizumab (Keytruda) monotherapy for the frontline treatment of patients with stage III non–small cell lung cancer (NSCLC), who are ineligible for surgery or definitive chemoradiation, or metastatic NSCLC, with a PD-L1 expression (tumor proportion score [TPS]) level of ≥1% and do not harbor EGFR or ALK aberrations.

The FDA expanded the indication for for pemetrexed (Alimta) injection plus pembrolizumab (Keytruda) and platinum-based chemotherapy for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) without EGFR or ALK alterations.

The immunotherapy agent showed promise in pre-treated patients with the disease.

The FDA has granted an approval to the combination of atezolizumab (Tecentriq) with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).